Team uses AlphaFold AI to redesign gene-editing proteins to make them safer

Gene-editing therapies are finally becoming clinical reality, but they've faced a critical safety challenge: off-target effects, where the editing machinery accidentally modifies the wrong DNA sequences. Researchers publishing in Nature, per Ars Technica, used AlphaFold to identify which parts of gene-editing proteins were causing these errors, then redesigned those regions to reduce off-target mistakes. The result is a practical path toward safer, more reliable therapies for patients.

Listen to this story

Hear this and more stories in a personalized audio briefing.

Open The Chonkerton